Here are the 424B prospectus supplements from Curis Inc (CRIS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CRIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRIS filings page.
Curis, Inc. is conducting a primary offering of 335,001 shares of common stock, 3,398,333 pre-funded warrants and 3,733,334 August 2026 common warrants, at a combined public offering price of $1.50 per share and warrant or $1.49 per pre-funded warrant and warrant, for total gross proceeds of $5.6 million. Net proceeds are estimated at $4.8 million after a 6.5% placement fee and expenses, and are intended to fund research and development for emavusertib, working capital and general corporate purposes.
The warrants are immediately exercisable, with pre-funded warrants priced at a $0.01 exercise price per share and August 2026 Warrants at $1.75 per share, expiring five years after issuance, and subject to 4.99%–9.99% beneficial ownership caps. As of March 31, 2026 Curis held $15.0 million in cash and equivalents, had an accumulated deficit of $1.3 billion, and reported a quarterly net loss of $24.2 million. The company states that existing cash plus this offering are not expected to fund operations beyond 12 months and explicitly discloses substantial doubt about its ability to continue as a going concern.
Curis, Inc. filed a prospectus supplement dated August 8, 2025 registering an at-the-market (ATM) program to sell up to $8,137,047 of common stock through Cantor Fitzgerald & Co. and JonesTrading as sales agents, who will receive a 3% commission on gross sales. The offering is being made under an amended sales agreement and the shares may be sold from time to time at market prices.
The company focuses on emavusertib (CA-4948), an orally available IRAK4 inhibitor licensed via a 2015 collaboration with Aurigene, and has licensed Erivedge rights to Genentech. As of June 30, 2025 Curis had $10.1 million in cash and cash equivalents and completed July 2025 offerings that generated approximately $6.0 million net proceeds. Management states that existing cash plus July proceeds should fund operations into the first quarter of 2026, but the company discloses substantial doubt about its ability to continue as a going concern beyond 12 months. Curis also faces a Nasdaq market-value deficiency and must regain a $35 million market value by August 20, 2025 to avoid delisting.